As previously disclosed, in late Q3 2022, the Company began to experience material supply issues related to its ALLOCYTE ® Advanced Cellular Bone Matrix (“ALLOCYTE”) product line. The supply ...

BBLG READ THE FULL BBLG RESEARCH REPORT Bone Biologics (NASDAQ:BBLG) is a clinical-stage biotechnology company focused on transforming the multibillion-dollar spine fusion and bone regeneration market ...

Vivex Biologics, Inc., a leading medical technology company developing and delivering innovative allografts for ...

Sean Browne, President and CEO of Xtant Medical, stated, "New product launches are a key component of our strategy to drive margin improvement on higher sales and generate positive operating cash flow ...

BURLINGTON, Mass.--(BUSINESS WIRE)-- Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announces it has entered into a supply agreement with ...

Our results tend to support these overall findings of reliable remodelling of DBM to new bone. The histological analysis showed significant new bone formation and decreasing residual DBM material in ...

SAN FRANCISCO & PARSIPPANY, N.J.--(BUSINESS WIRE)--Ossium Health®, a bioengineering company that established a first-of-its-kind bone marrow banking platform, has entered into a collaborative ...

A new study of the PhyloBone project of the University of Turku, Finland, identifies hundreds of non-collagenous proteins in the bone matrix that may play regulatory roles in bone formation and ...

ViviGen ® Cellular Bone Matrix, an innovative cellular allograft developed by LifeNet Health and marketed in collaboration with DePuy Synthes Spine, received one of the highest honors in spinal ...